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ABSTRACT
The endogenous incretins, glucose-dependent insulinotropic polypeptide 
and Glucagon-like peptide, are peptide hormones secreted from endocrine 
cells in the small intestine. Glucagon-like peptide-1 stimulates insulin 
and suppresses glucagon secretion, delays gastric emptying, and reduces 
appetite and food intake, which explains the positive effect of incretin 
mimetics on weight. The incretins have also been shown to have a sustained 
improvement in glycemic control over three years. A wide range of 
cardiovascular benefits have also been claimed, such as lowering of blood 
pressure and postprandial lipids. Clinical trials with the incretin mimetic 
exenatide and liraglutide show reductions in fasting and postprandial glucose 
concentrations, and haemoglobin A1c (1–2%), associated with weight loss 
(2–5 kg). The most common adverse event associated with Glucagon-like 
peptide-1 receptor agonists is nausea, which lessens over time. Orally 
administered Dipeptidyl Peptidase-4 inhibitors reduce hemoglobin A1c by 
0·5–1·0%, with few adverse effects and no weight gain. These new classes of 
anti-diabetic agents also expand β-cell mass in preclinical studies. However, 
long-term clinical studies are still needed to determine the benefits of 
incretin for the treatment of type 2 diabetes.
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INTRODUCTIONS
In the 1960s, data suggested that oral glucose elicited a 
much greater secretion of insulin than a similar amount 
of glucose administered intravenously1 and that this 
potentiating of insulin secretion by the gut may be 
responsible for up to 70% of the insulin response to a 
meal.2, 3 This physiologic activity was subsequently 
referred to as the intestinal secretion of insulin, or 
incretin effect. It was later found that two hormones and 
glucagon-like peptide-1 are responsible for the incretin 
effect.3  A key feature of glucagon-like peptide-1 action 
is the glucose-dependent stimulation of insulin secretion 
and concomitant suppression of glucagon. Thus, 
pharmacologic efforts to develop medications that mimic 
the actions of GLP-1 have become a target for improving 
or reversing chronic hyperglycemia. Dipeptidyl-like 
peptidase-4 inhibitors - sitagliptin and vildagliptin are the 
first agents in this class to have received FDA approval, in 
addition to saxagliptin and linagliptin.
The Antidiabetic Actions of Incretin Hormones: As 
knowledge  of  the  pathophysiologic mechanisms   of 
diabetes   mellitus   has increased,  clinical  attention 
has  shifted to   the   incretin   system.6 Hormones 
secreted from gastrointestinal endocrine cells   play   key 
roles   in the control of energy balance by regulating 
the assimilation, storage, and metabolic processing of 
nutrients.7 Disruption   of   these endocrine cells disturbs 
the normal control   of   insulin  production   and   body 
weight, contributing to the development of Diabetes 
Mellihas Type 2. Two incretin hormones, GLP-1 and GIP, 
are vital to the control of glucose homeostasis through 
their ability to increase the β-cell   insulin response to 
ingested glucose.6,7 These hormones are responsible 
for more than 90% of the incretin effect observed after 
glucose ingestion.6
GLP-1 and GIP are released  within minutes  of  glucose 
absorption to increase insulin secretion.8 GLP-1  is 
synthesized in  L-cells  in  small  bowel  and colon, whereas 
GIP is secreted by K-cells in the duodenum and proximal 
jejunum. Both GLP-1 and GIP trigger insulin tropic actions 
by binding to β-cell receptors.  GLP-1  receptors are 
primarily  expressed  on  pancreatic glucagon-containing 
α, β and δ cells, though  they  are  also  widely  expressed 
in   the  central   and peripheral  nervous  system,  lung, 
heart, and  gastrointestinal  tract.8,9 GLP -1  and  GIP  exert 
multiple biological  effects.10 The metabolic effects of 
GLP-1  include: inhibiting glucose-dependent  glucagon 
secretion from α cells; increasing β-cell proliferation and 
decreasing  β-cell  apoptosis; slowing   gastric emptying; 
increasing CNS-mediated satiety leading to reduced 
food intake; indirectly increasing insulin sensitivity and 
nutrient uptake in skeletal muscles and adipose tissue; 
and exerting neuroprotective effects.9,10
The metabolic effects   of   GIP   include,   in  addition 
to increasing insulin secretion, the following: inhibiting 
gastric acid secretion; bio-regulating fat metabolism in 
adipocytes; increasing  glucagon secretion; increasing 
β-cell  replication; and decreasing β-cell apoptosis.9,10 
Under  normal  physiologic  conditions,  fasting  plasma 
glucose  (FPG)  is managed by tonic insulin and glucagon 
secretion, but excursions of pat pran dialglucose are 
controlled  by  insulin  and  the  incretin  hormones.9 
Several key pathologic abnormalities characteristic of 
T2DM appear to be related   to   the   biologic   activities 
and functions   of   incretins. Patients   with T2DM  have 
impaired incretin function, impaired GLP-1 release, 
diminished insulinotropic response to GIP, glucoregulatory 
defects,   and impaired glucose homeostasis.6,9 Table 1 
lists  the  effects  of  GLP-1  and  GIP  on defects in glucose 
metabolism, pancreas function,  and  energy  uptake  in 
patients with  T2DM.11 Importantly, the  incretin effect in 
particular,  postprandial production of GLP-1 is   impaired 
in patients with T2DM. The insulin-secretory response, 
however, can be restored with pharmacologic doses of 
GLP-1.12 
Table 1. Action of incretins GLP-1 and glucose dependent insulotrophic 
polypeptide on pathophysiologic defects in patients with type 2 
diabetes mellitus. 11
Defects in Type 2 Diabetes Action of Incretins
Impaired glucose stimulated 
insulin secretion and first phase 
response
Restoration of glucose dependent insulinotropic 
effect and lack of postparandial biphasic 
response
Hypergluccagonemia Supression of glucagon secretion
Defective hypoglycaemia counter 
regulation
Glucagon secretion and loss of insulinotropic 
effect, when plasma glucose is low
Reduced beta cell mass and insulin 
content
Increased synthesis of proinsulin, possible 
increased beta cell mass or differentiation of 
islet precursor cells into beta cells
Accelerated beta cell apoptosis Possible inhibition of toxin induced beta cell apoptosis
Normal retarded or accelerated 
gastric emptying Slowing of gastric emptying
Hypercaloric energy intake, obesity Supression of appetite/increase satiety, weight loss
Incretin-Based Treatment Options: Glucagon-like 
peptide-1 is rapidly metabolized by the enzyme DPP-4, 
resulting in the generation of an inactive compound that 
makes for a nonviable therapeutic agent.7 As a result, a 
number of of GLP-1 homologs (exenatide and lixisenatide) 
or analogs (liraglutide, dulaglutide, and albiglutide), and 
inhibitors of DPP-4(sitagliptin, vildagliptin, linaglutin and 
sexagliptin) have been developed as options for treating 
patients with T2DM. GLP-1  receptor  agonists  can 
produce  GLP-1  levels  that  are more than five times a 
patient’s physiologic levels, and DDP-4 inhibitors result in 
an approximate  two-fold  increase  in  GLP-1 levels.13
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GLP-1 Receptor Agonists Exenatide (synthetic exendin-4): 
Its first incretin-related therapy available for patients with 
type 2 diabetes. It is naturally occurring peptide from 
the saliva of the Gila monster and has an approximate 
50% amino acid homology with GLP-1. It binds to GLP-1 
receptors and mimics many properties of GLP-1. GLP-1 is 
degraded within one to two minutes by DPP-IV within one 
to two minutes of entering the circulation. But exenatide 
is resistant to DPP-IV inactivation. Moreover, it is >1000 
times more potent than GLP-1 in circulation. It does not 
stimulate gastric acid secretion or trigger hepatic vagal 
efferent. Following injection, it is measurably present 
in plasma for up to 10 hours and therefore suitable for 
twice a day administration by subcutaneous injection.14 
Exenatide is excreted renally so, it is contraindicated in 
patients with decreased creatinine clearance (CrCl <30 
mL/min) or with end-stage renal disease (ESRD).17
Most recently, a multicenter placebo-controlled trial,15 
evaluated the safety and efficacy  of twice-daily exenatide 
in patients whose T2DM was uncontrolled with insulin 
glargine, with or without oral antihyperglycemic agents. 
Patients receiving exenatide (n=138) had a mean HbA1c 
reduction of 1.74%, compared to 1.04 % in patients 
receiving placebo (n=123) (between-group difference, 
-0.69; 95%   confidence   interval (CI), -0.93% to -0.46%; 
p<.001).   Body weight decreased  by  an  average  of 
1.8  kg  with exenatide and increased by an average of 
1.0 kg with placebo (between-group difference, -2.7 
Kg;  95%  CI,  -3.7 Kg to -1.7 Kg;  p<.001).  The incidence 
of minor hypoglycemia was similar between the two 
groups. The rates of hypoglycemia observed in patients 
taking exenatide are largely dependent on the agents 
with which it is combined. However, patients receiving 
exenatide experienced higher rates of gastrointestinal 
adverse effects compared to those receiving placebo.15 
Two clinical studies18,19 of exenatide (5 μg or 10 μg once 
daily) demonstrated mean increases in the homeostasis 
model assessment–β-cell (HOMA-B) index, a commonly 
used measure  of  β-cell  function,  of  19%  at  24 weeks 
and 32% at 30 weeks. In patients with  T2DM,  exenatide 
normalizes  the loss  of  first-phase  insulin  secretion  and 
glucagon  hypersecretion from  β cells,  thereby  reducing 
hepatic  glucose production in the postprandial state.16  
Guidelines from both the National Institute for Health and 
Clinical Excellence (NICE) and the Scottish Intercollegiate 
Guidelines Network (SIGN) have recommended using 
exenatide and liraglutide as third-line agents in obese 
(body mass index (BMI) >30 kg/m2) patients who do not 
meet glycaemic targets on a combination of metformin 
and a sulphonylurea.
Long Acting Exenatide: Preliminary experience with 
exenatide LAR in 45 patients with type 2 diabetes indicates 
a much greater reduction in fasting glucose concentrations 
and HbA1c after once weekly administrations of 
exenatide LAR for 15 weeks compared with exenatide 
twice daily.24 A recent study comparing 2 mg preparation 
of exenatide –LAR given once weekly with conventional 
exenatide 10 mcg given twice daily showed a greater 
reduction in HbA1c levels with exenatide –LAR and highly 
effective with once weekly injection. However, nausea 
has been reported less frequently with once weekly 
than with twice daily administration (26% versus 50%).25 
Liraglutide: Liraglutide is a GLP-1analogue with 97% 
sequence identity to the human hormone. Liraglutide 
contains a single amino acid substitution relative to 
endogenous GLP-1 and is linked to a fatty acid chain, 
resulting in slow absorption into circulation, increased 
reversible albumin binding, and reduced susceptibility 
to DPP-4. These effects extend liraglutide’s benefits, 
increasing its plasma half-life to 11 to 15 hours.20,21 with 
maximal concentration after eight to twelve hours.22 
Injected once daily, at any time of day, irrespective of 
meals, liraglutide reduced fasting blood glucose and 
glycemic excursions associated with all meals.14
In LEAD-1, LEAD-2, and LEAD-4, researchers tested the 
use of liraglutide combined with glimepiride, metformin, 
or metformin and rosiglitazone, respectively. These 
combination regimens reduced mean HbA1c levels 
by more than 1% over 26 weeks.27-29 In LEAD-5, once-
daily liraglutide was compared directly with insulin 
glargine in patients receiving concomitant metformin 
and glimepiride.30 Liraglutide led to significantly lower 
HbA1c levels compared with glargine (p=.0015). As is 
commonly observed following transition to insulin,31 
patients starting glargine gained weight. Convercsely, 
those administered liraglutide lost weight, with a 
difference of 3.5 kg at study’s end.30 The final LEAD study, 
LEAD-6, offers a head-to-head comparison between the 
two GLP-1 receptor agonists.32 In this study, liraglutide 
and exenatide both significantly reduced HbA1c levels 
relative to baseline. However, the extent of this reduction 
was significantly greater for liraglutide (p<0.0001). 
Treatment-associated nausea declined with time for both 
study arms but persisted longer in patients treated with 
exenatide. Analysis across the available LEAD studies 
shows a consistent improvement in HbA1c levels with 
liraglutide (1.0% to 1.6%), and a very low incidence of 
hypoglycemic episodes. In addition, liraglutide treatment 
was associated with sustained weight loss, systolic blood 
pressure reduction, and improved β-cell function.29,30, 32
There have been reports suggesting that both treatments 
with exenatide,33 and liraglutide,34 the most common GLP-
1 receptor agonists, are associated with an increased risk 
of pancreatitis. As chronic pancreatitis is also a known 
risk factor for pancreatic cancer through cytotoxicity 
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of inflammatory cytokines, reactive oxygen species, 
and proliferation,35 there might be an increased risk of 
pancreatic cancer as well. It has also been observed in 
preclinical studies that incidence of thyroid C- cell tumors 
was increased in rodents treated with GLP-1 analogs.36 
Therefore, monitoring f or thyroid cancer has been a 
focus in the clinical development plans of all DPP-4 
inhibitors and GLP-1 receptor agonists, but thus far the 
data have been reassuring.
Taspoglutide: Another extended release molecule works 
on a once weekly basis promising results in phase 2 
studies. Tapsoglutide has a 93% homology to endogenous 
GLP-1. The development of tapsoglutide was recently 
discontinued because of hypersensitivity concerns, 
an effect that has not been seen with any of the other 
approved or experimental GLP-1 mimetics.
Albiglutide: It is a human GLP-1 receptor agonists with 
two molecules of GLP-1 linked to albumin. The half life is 
about five days making once weekly dosing possible. In 
phase 2 trials, HbA1c reduction observed after 16 weeks 
were similar for dosages 30 mg weekly, 50 mg bi-weekly 
and 100 mg monthly.
DPP4 Inhibitors: Oral DPP4 inhibitors increase the 
availability of endogenous GLP-1, thus enhancing glucose-
induced insulin secretion and inhibiting glucagon release. 
These agents have no effect on gastric emptying,38, 39 and 
do not affect body weight.37 
Sitagliptin and Vildagliptin: Sitagliptin and vildagliptin 
are the first agents in this class to have received FDA 
approval. Sitagliptin is potent, highly selective, reversible 
and competitive inhibitor of DPP-4 enzyme and exerts its 
anti-hyperglycemic effect by slowing the inactivation of 
incretin hormones. Sitagliptin has been associated with 
an approximate two-fold increase in postprandial GLP-1 
plasma concentrations,   compared   to placebo in healthy 
human study participants and in patients with T2DM.40,41 
A comprehensive meta-analysis of trials of once-daily 
sitagliptin (available in Canada and elsewhere) or twice-
daily vildagliptin (marketed in Europe) concluded that 
these agents were well tolerated,42 although infections 
including nasopharyngitis, upper respiratory tract 
infections, and urinary tract infections, were significantly 
increased with sitagliptin (relative risk 1.15 compared 
with placebo 95% confidence interval 1.02 to 1.31;p=.03). 
They are indicated as monotherapy and in combination 
with metformin, thiazolidinedione (TZD) and insulin. 
Headache was reported for both drugs but was more 
common in patients taking vildagliptin.42 
Because sitagliptin is cleared by the kidneys, dosage 
adjustments are recommended in patients with 
moderate to severe renal insufficiency and in patients 
undergoing dialysis.  For patients with moderate renal 
insufficiency (Crcl 30-50 ml/min), the sitagliptin dose 
should be reduced to 50 mg.  For patients with severe 
renal   insufficiency  (Crcl  <30 ml/min)  or  end-stage 
renal  disease,  a sitagliptin  dose reduction  to  25 mg  is 
indicated.44 Vildagliptin is not recommended for use in 
moderate renal failure.
Saxagliptin: Saxagliptin is another DPP-4 inhibitor 
approved by FDA for the treatment of patients with 
T2DM.45 It is a potent,  reversible, competitive  agent 
that  selectively  inhibits DPP-4.46 As with sitagliptin, 
saxagliptin exerts its glucoregulatory actions through 
prevention of   incretin  degradation, leading to 
potentiation of GLP-1 and GIP action.46 The efficacy of 
saxagliptin has been studied as monotherapy and in 
combination with metformin, sulfonylureas, and TZDs. 
During 24 to 102 weeks of treatment with saxagliptin, 
glycemic efficacy  has  been  demonstrated  in  patients 
with  T2DM  regardless  of  age,  gender, race/ethnicity,  or 
body  weight.46 When used as monotherapy, saxagliptin 
5 mg once daily produced mean HbA1c reductions of 
0.5% to 0.7%.46,47 When  used  in combination with 
traditional oral hyperglycemic  agents,  saxagliptin  5 mg 
once daily (as add-on therapy or as initial combination 
therapy)   provided   clinically important  reductions  in 
HbA1c level.46  Saxagliptin, when used with metformin, 
produced   mean   reductions   in   HbA1c levels of  0.7% 
to 2.5%,53,54  when  used with a sulfonylurea, HbA1c mean 
reduction  was  0.6% 60;  and  when  used  with  a TZD, 
HbA1c mean reduction was 0.9%.48
The usual dose of saxagliptin is 2.5 or 5 mg once daily, 
with 2.5  mg dose  recommended  for patients  with 
moderate  to severe  kidney disease (CrCl <50 mL/min) 
and for patients taking strong CYP3A4/5 inhibitors, 
such as ketoconazole.46 The most  common  adverse 
events observed with saxagliptin are similar to those of 
sitagliptin, such  as  headache, nasopharyngitis, upper 
respiratory tract infections, and urinary tract infections.46
Linagliptin: In  May 2011,  linagliptin became  the  latest 
DPP-4  inhibitor  to  be approved by the FDA for the 
treatment of   patients with T2DM.49 Similar to sitagliptin 
and saxagliptin, linagliptin is a potent, highly selective, 
DPP-4 inhibitor.50 In approximately 4000 patients with 
T2DM in clinical trials, linagliptin as monotherapy or in 
combination with other oral antihyperglycemic drugs 
was generally well tolerated, with a low incidence of 
hypoglycemia.50 The usual dose of linagliptin is 5 mg 
once daily. No dose adjustment is needed in patients 
with renal or hepatic impairment. Inducers of CYP3A4 
(eg Rifampin) may decrease the efficacy of linagliptin. 
Therefore, patients requiring such drugs should receive 
an alternative to linagliptin.
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Table 2. Comparison of DPP-4 and GLP-1 RAs.52
Effects/parameters DPP-4 inhibitors GLP-1 receptor agonists
Route of administration Oral Subcutaneous injection
Dose/timing of 
administration Once daily
Once or twice daily or once 
weekly
A1c reduction 0.5%-1.0% 0.6-1.9%
Body weight Neutral Reduced
Hypoglycemic Low incidence Low incidence
Insulin secretion Enhanced Enhanced
Post prandial hyperglycemia Reduced Reduced
Glucagon secretion Suppressed Suppressed
Appetite No effect Suppressed
Gastric emptying No effect Slowed (Short acting agent)
Gastrointestinal None Nausea, diarrhea, vomiting
GLP-1Receptor Agonists versus DPP-4 Inhibitors: Various 
similarities and differences exist between GLP-1 receptor 
agonists and DPP-4 inhibitors.51,52 Among  the differences 
between these two drug classes, GLP-1 receptor agonists 
are administered via subcutaneous injection, while DPP-
4 inhibitors are delivered as oral tablets. Glucagon-like 
peptide-1 receptor agonists are probably more effective 
than DPP-4 inhibitors at reducing HbA1c levels (Table2).52 
Glucagon-like peptide-1 receptor agonists help preserve 
β cells, which are diminished with DPP-4 inhibitors; 
induce weight loss, unlike DPP-4 inhibitors; and have 
beneficial effects on blood pressure that, have not been 
demonstrated   with   DPP-4 inhibitors.51,52
FUTURE DEVELOPMENTS
Many new   incretin-based   agents   are under investigation 
for the treatment of patients with T2DM.  Albiglutide, 
exenatide LAR, and lixisenatide are investigational GLP-1 
receptor agonists in late stages of clinical development.55 
Liraglutide and exenatide are first-generation GLP-1 
receptor agonists, requiring once or twice daily parenteral 
administration, respectively. Much effort continues to be 
directed towards improvement of the pharmacokinetic 
profile of GLP-1R agonists, to minimize peak levels of the 
drug and thus reduce the extent of nausea. Longer-acting 
GLP-1R agonists should ideally provide more uniform 
and sustained GLP-1R activation over a 24-h period, but 
require less frequent administration.
CONCLUSIONS
The treatment of patients with T2DM remains complex 
and challenging for physicians. Because GLP-1 receptor 
agonists work in a glucose-dependent manner, they are 
likely to reduce hyperglycemia safely, without a marked 
fluctuation toward hypoglycemia. In the process of 
acutely restoring β-cell function, GLP-1 agonists may allow 
patients to achieve HbA1c <7%, without experiencing 
weight gain or hypoglycemia. These incretin-based 
medications demonstrate improved efficacy and safety 
relative to traditional agents, and they represent a major 
paradigm shift in the treatment of patients with diabetes 
mellitus and might be considered as first-line therapy 
after metformin, and insulin therapy (mainly long-acting 
analogs) could be added if A1C is not at target, mainly 
when fasting or pre-prandial glucose levels are high. The 
safety of constant DPP-4 or GLP-1therapy over time is 
not yet fully clear. Presently, the benefits of using DPP-
4 inhibitors or GLP-1 receptor agonists for treatment of 
type 2 diabetes outweigh the risks. Nonetheless, their 
safety profile should be monitored and their indications 
should be widened cautiously.
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